OKYO PHARMA LTD Aktie

OKYO Pharma Ltd (NASDAQ:OKYO) told investors that it is on track to release top-line results from its phase 2 clinical trial of OK-101 to treat dry eye disease (DED) this month after the last patient completed the 12-week OK-101 dosing study. The clinical-stage drug developer said data analysis plans for the 240-patient double-blind placebo-controlled trial have now been finalized and submitted to the US Food and Drug Administration (FDA) for feedback, in anticipation of database lock, subsequent data analysis, and reporting of top-line findings on OK-101. » Mehr auf proactiveinvestors.com

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer noted, told investors it has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for the development of OK-101 to treat Neuropathic Corneal Pain (NCP).  According to the company, there is no FDA-approved drug to treat NCP, which remains a major unmet medical need for the ocular community. » Mehr auf proactiveinvestors.com

OKYO Pharma Ltd (NASDAQ:OKYO), the clinical-stage drug developer, has reported encouraging safety data for its ongoing phase II clinical trial of OK-101, a drug candidate aimed at treating dry eye disease (DED). The trial, which involves 240 patients, is designed to assess the safety, efficacy, and tolerability of OK-101. » Mehr auf proactiveinvestors.com